Xu Xuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xu Xuan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Mi Liu
School of Acupuncture-moxibustion, Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, China
2 shared publications - Bo Huang
School of Acupuncture & Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication - Chang She
Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital), Changsha, Hunan, 410002, China
1 shared publication - Haihua Xie
College of Acupuncture & Tuina and Rehabilitation, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China
1 shared publication He Haolong
1 shared publication- Jia Jiang
School of Acupuncture & Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha 410208, China
1 shared publication
Latest Publications
- Open Access
- 6 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1373
The Role of Gut Microbiota-Derived Trimethylamine N-Oxide in the Pathogenesis and Treatment of Mild Cognitive Impairment
Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia, often considered critical for dementia prevention. Despite its significance, no effective clinical treatment for MCI has yet been established. Emerging evidence has demonstrated a strong association between trimethylamine-N-oxide (TMAO), a prominent metabolite derived from the gut microbiota, and MCI, highlighting its potential as a biomarker and therapeutic target. TMAO has been implicated in increasing MCI risk through its influence on factors such as hypertension, cardiovascular disease, depression, diabetes, and stroke. Moreover, it contributes to MCI by promoting oxidative stress, disrupting the blood–brain barrier, impairing synaptic plasticity, inducing inflammation, causing mitochondrial metabolic disturbances, and facilitating abnormal protein aggregation. This review further explores therapeutic strategies targeting TMAO to mitigate MCI progression.
- 6 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1373
Open AccessThe Role of Gut Microbiota-Derived Trimethylamine N-Oxide in the Pathogenesis and Treatment of Mild Cognitive Impairment
Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia, often considered critical for dementia prevention. Despite its significance, no effective clinical treatment for MCI has yet been established. Emerging evidence has demonstrated a strong association between trimethylamine-N-oxide (TMAO), a prominent metabolite derived from the gut microbiota, and MCI, highlighting its potential as a biomarker and therapeutic target. TMAO has been implicated in increasing MCI risk through its influence on factors such as hypertension, cardiovascular disease, depression, diabetes, and stroke. Moreover, it contributes to MCI by promoting oxidative stress, disrupting the blood–brain barrier, impairing synaptic plasticity, inducing inflammation, causing mitochondrial metabolic disturbances, and facilitating abnormal protein aggregation. This review further explores therapeutic strategies targeting TMAO to mitigate MCI progression.
- Open Access
- 24 January 2024
- Published by IntechOpen
Complementary replacement therapy for chronic gastritis
Gastritis, an inflammation of the stomach lining, arises from diverse causes and ranks among the most frequent digestive ailments. It typically falls into two categories based on the speed of onset: acute and chronic gastritis. Patients with acute gastritis are generally managed symptomatically. Meanwhile, those with chronic gastritis experience ongoing discomfort like epigastric pain, belching, and acid reflux, negatively impacting their quality of life. They can benefit from presently approved medical treatments. To alleviate the physical and mental burden of chronic gastritis and enhance life quality, many patients explore complementary and alternative therapies (CAM). A wide array of CAM options exists, but their safety and effectiveness remain uncertain. If supported by robust evidence, these therapies could potentially become part of standard medical practice for treating chronic gastritis. Approaches like Traditional Chinese Medicine, Acupuncture, Tuina, Diet, Exercise, and Psychological Interventions have demonstrated the capacity to ameliorate symptoms and enhance the well-being of chronic gastritis patients. Identifying high-quality evidence regarding efficacy and safety through Randomized Controlled Trials (RCTs) can facilitate the broader integration of CAM in chronic gastritis treatment. This section offers an overview of the most recent clinical trial findings concerning complementary and alternative therapies.
- 24 January 2024
- Published by IntechOpen
Open AccessComplementary replacement therapy for chronic gastritis
Gastritis, an inflammation of the stomach lining, arises from diverse causes and ranks among the most frequent digestive ailments. It typically falls into two categories based on the speed of onset: acute and chronic gastritis. Patients with acute gastritis are generally managed symptomatically. Meanwhile, those with chronic gastritis experience ongoing discomfort like epigastric pain, belching, and acid reflux, negatively impacting their quality of life. They can benefit from presently approved medical treatments. To alleviate the physical and mental burden of chronic gastritis and enhance life quality, many patients explore complementary and alternative therapies (CAM). A wide array of CAM options exists, but their safety and effectiveness remain uncertain. If supported by robust evidence, these therapies could potentially become part of standard medical practice for treating chronic gastritis. Approaches like Traditional Chinese Medicine, Acupuncture, Tuina, Diet, Exercise, and Psychological Interventions have demonstrated the capacity to ameliorate symptoms and enhance the well-being of chronic gastritis patients. Identifying high-quality evidence regarding efficacy and safety through Randomized Controlled Trials (RCTs) can facilitate the broader integration of CAM in chronic gastritis treatment. This section offers an overview of the most recent clinical trial findings concerning complementary and alternative therapies.